Inhibrx Biosciences (INBX) Stock Analysis

What Inhibrx Biosciences does

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.

Key metrics

ETFs linked to INBX

Broad-market and Healthcare sector ETFs an investor holding Inhibrx Biosciences is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how INBX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Inhibrx Biosciences?

Inhibrx Biosciences trades under the ticker INBX on NASDAQ.

Which exchange is INBX listed on?

INBX is listed on NASDAQ.

What sector does Inhibrx Biosciences operate in?

Inhibrx Biosciences is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze INBX in a portfolio?

PortView shows INBX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.